Aquagenic Pruritus in Myeloproliferative Neoplasms

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04018209

Acronym

PANAM

Enrollment

170

Registered

2019-07-12

Start date

2019-07-09

Completion date

2021-01-06

Last updated

2024-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms

Keywords

Pruritus, Myeloproliferative Neoplasms

Brief summary

Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms. Prospective work based on the distribution of a dedicated questionnaire.

Detailed description

Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis. Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated or not) suffering from aquagenic pruritus. Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). * Suffering (or having suffered) from aquagenic pruritus. * No age limit, but major * Patient having formulated his non-opposition

Exclusion criteria

* Patients with MPN with non-aquagenic pruritus, * Patients with another hematologic disease and aquagenic pruritus * Patients unable to complete the questionnaire. * Patients with physical or mental disabilities to formulate non-opposition * Refusal of participation

Design outcomes

Primary

Measure	Time frame	Description
Description of pruritus in patients with myeloproliferative neoplasms	at the time of questionnaire completion (Day 0)	Intensity of pruritus (visual analogic scale)

Secondary

Measure	Time frame	Description
Description of therapies used to treat pruritus	at the time of questionnaire completion (Day 0)	Name of drugs used

Countries

France

Outcome results